NASHVILLE, Tenn., April 11 /PRNewswire/ -- Cumberland Emerging Technologies (CET) has announced the signing of a collaboration agreement with the University of Mississippi School of Pharmacy (UM) to develop and commercialize new pharmaceutical products. With the shared goal of bringing early-stage research to the marketplace, the parties have agreed to combine their strengths to take innovative new products, based on research at UM, through the critical phases of development and on to commercialization. The university and CET will work together to pursue grant funding for these projects through programs like Small Business Technology Transfer and Small Business Innovation Research, for which CET will provide program management. In addition to bringing new products to market, the parties will explore opportunities for development of a Mississippi-based CET life sciences incubator, similar to the facility CET developed in Nashville in 2002. "We are excited to partner with CET to further the important work initiated here," said Barbara Wells, dean of the UM School Of Pharmacy. "The infrastructure support they provide will present our researchers with increased opportunity to develop potentially life-saving medications and technologies in our region." "Aligning ourselves with outstanding academic research and training programs like the University of Mississippi School of Pharmacy is a logical progression in CET's development," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals and CET. "By combining our expertise in drug development and commercialization with the university's research initiatives, we can facilitate the introduction of promising new products to the market." Founded in 1908, the UM School of Pharmacy ( http://www.pharmacy.olemiss.edu/ ) offers degree programs to undergraduate and graduate students. Through the campus-based Research Institute of Pharmaceutical Sciences and its two divisions, the National Center for Natural Products Research and the Center for Pharmaceutical Marketing and Management, the university conducts research to improve human health and agricultural productivity. The university's Division of Technology Management has successfully licensed 17 technologies over the past five years, including three pharmaceutical candidates in clinical trials. Cumberland Emerging Technologies, Inc. is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc. and the Tennessee Technology Development Corporation. The mission of CET ( http://www.cet-fund.com ) is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the commercial marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products.
SOURCE Cumberland Emerging Technologies, Inc.